Weekly docetaxel, cisplatin and low dose of fluorouracil for advanced gastric carcinoma: A randomized clinical trial

Tumor

Volumn 29, Issue 2, 2009, Pages 160-163

  Hou, An Ji ^a   Hu, Yan ^a   Zhou, Wei ^a   Zhang, Hong Wei ^a   Huang, Yan Li ^a   Shen, Xiao Yan ^a   Zhou, Li ^a   Gu, Wei Feng ^a  

^a SHANGHAI SEVENTH PEOPLE S HOSPITAL   (China)

Author keywords

Chemotherapy; Randomized clinical trial; Stomach neoplasms

Indexed keywords

CISPLATIN; DOCETAXEL; ETOPOSIDE; FLUOROURACIL; FOLINATE CALCIUM;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; STOMACH CARCINOMA; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 77953398521     PISSN: 10007431     EISSN: None     Source Type: Journal    
DOI: 10.3781/j.issn.1000-7431.2009.02.013     Document Type: Article

References (13)

1. LEE J, PARK CK, PARK JO, et al. Impact of E2F-1 expression on clinical outcome of gastric adenocarcinoma patients with adjuvant chemoradiation therapy[J]. Clin Cancer Res, 2008,14(1): 82-88.
2. MONRERO E, ABREU C, TONINO P, et al. Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas[J]. J Cancer Res Clin Oncol, 2008, 134(2):193-201.
3. LIN S Z, TONG H F, YOU T, et al. Palliative gastrectomy and chemotherapy for stage IV gastric cancer[J]. J Cancer Res Clin Oncol, 2008, 134(2):187-192.
4. ROTH AD, FAZIO N, STUPP R, et al. Docetaxel, cisplatin, and fluorouracil; docetaxel and cisplatin; and epirubicin, cisplatin, and fluorouracil as systemic treatment for advanced gastric carcinoma: a randomized phase II trial of the Swiss Group for Clinical Cancer Research[J]. J Clin Oncol, 2007, 25(22): 3217-3223.
5. CHIESA MD, BUTI S, TOMASELLO G, et al. A pilot phase II study of chemotherapy with oxaliplatin, folinic acid, 5-fluorouracil and irinotecan in metastatic gastric cancer[J]. Tumor, 2007, 93 (3):244-247.
6. MARUTA F, ISHIZONE S, HIRAGURI M, et al. A clinical study of docetaxel with or without 5′, DFUR as a second-line chemotherapy for advanced gastric cancer[J]. Med Oncol, 2007, 24 (1):71-75.
7. NERI B, PANTALEO P, GIOMMONI E, et al. Oxaliplatin, 5-fluorouracil/leucovorin and epirubicin as first-line treatment in advanced gastric carcinoma: a phase II study[J]. Br J Cancer, 2007, 96(7):1043-1046.
8. Chinese source.
9. KIM D, JOO J K, RYU S Y, et al. Clinicopathological characteristics and prognosis of carcinoma of the gastric cardia[J]. Dig Surg, 2006, 23(5-6):313-318.
10. PAPADAKOU M, XYDAKIS E, BONIOS M, et al. Adjuvant che-motherapy with cisplatin, etoposide, fluorouracil and leucovorin for gastric carcinoma[J]. JBUON, 2006, 11(3):285-289.
11. KUNISAKI C, AKIYAMA H, NOMURA M, et al. Clinicopathological features of gastric carcinoma in younger and middle-aged patients: a comparative study[J]. J Gastrointest Surg, 2006, 10 (7):1023-1032.
12. DEL CSASR J M, CORTE M D, ALVARER A, et al. Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance[J]. J Cancer Res Clin Oncol, 2008, 134(2):153-161.
13. KIVILAAKSO E. Gastric carcinoma[J]. Scand J Surg, 2006, 95 (4):215-217.